PE20060575A1 - Derivados de amino-tropano como agonistas de los receptores de melanocortinas - Google Patents

Derivados de amino-tropano como agonistas de los receptores de melanocortinas

Info

Publication number
PE20060575A1
PE20060575A1 PE2005000887A PE2005000887A PE20060575A1 PE 20060575 A1 PE20060575 A1 PE 20060575A1 PE 2005000887 A PE2005000887 A PE 2005000887A PE 2005000887 A PE2005000887 A PE 2005000887A PE 20060575 A1 PE20060575 A1 PE 20060575A1
Authority
PE
Peru
Prior art keywords
cycloalkyl
alkyl
agonists
oct
amino
Prior art date
Application number
PE2005000887A
Other languages
English (en)
Inventor
Alain Braun
Bruno Cornet
Olivier Crespin
Cecile Pascal
Giles Courtemanche
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of PE20060575A1 publication Critical patent/PE20060575A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A COMPUESTOS DE FORMULA(I), EN DONDE Ra; Ra' Y R5 SON INDEPENDIENTEMENTE H, ALQUILO, CICLOALQUILO; R1 ES H, ALQUILO, CICLOALQUILO, HETEROCICLOALQUILO O ARILO; R2 ES -(CH2)X-(CO)Y- Y -(CO)Y-(CH2)X-Y, EN DONDE Y ES H, OH, ALQUILO, CICLOALQUILO, ENTRE OTROS; R3 ES DE 1 A 3 GRUPOS DE HALOGENO, ALQUILO, CICLOALQUILO, -OR, -NRR=, ENTRE OTROS; R4 ES a), b) O c), EN DONDE X ES O O S, O UN ANILLO -C(R7)(R6) O -N(R10), O ES -A-R18, -A-CH=N-R19, ENTRE OTROS. SON PREFERIDOS: N-[8-(4-CLORO-N-PIPERIDIN-4-IL-D-FENILALANIL)-8-AZABICICLO[3.2.1]OCT-3-IL]-N-CICLOHEXIL-N',N'-DIETILUREA, N-[8-(N-8-AZABICICLO[3.2.1]OCT-3-IL-4-CLORO-D-FENILALANIL)-8-AZABICICLO[3.2.1]OCT-3-IL]-N-CICLOHEXIL-N',N'-DIETILUREA, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE ELABORACION Y UNA COMPOSICION FARMACEUTICA. ESTOS COMPUESTOS SON AGONISTAS DE LOS RECEPTORES DE MELANOCORTINAS Y EN PATICULAR DEL RECEPTOR MC3 Y/O MC4, Y SON UTILES EN EL TRATAMIENTO Y PREVENCION DE OBESIDAD, DIABETES, DISFUNCIONES SEXUALES, ENFERMEDADES CARDIOVASCULAES E INFLAMATORIAS
PE2005000887A 2004-07-29 2005-08-01 Derivados de amino-tropano como agonistas de los receptores de melanocortinas PE20060575A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0408372A FR2873693B1 (fr) 2004-07-29 2004-07-29 Derives d'amino-tropane, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
PE20060575A1 true PE20060575A1 (es) 2006-08-02

Family

ID=34947491

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000887A PE20060575A1 (es) 2004-07-29 2005-08-01 Derivados de amino-tropano como agonistas de los receptores de melanocortinas

Country Status (26)

Country Link
US (1) US7569582B2 (es)
EP (1) EP1773829B1 (es)
JP (1) JP2008508242A (es)
KR (1) KR20070047803A (es)
CN (1) CN101010320B (es)
AR (1) AR050019A1 (es)
AT (1) ATE417846T1 (es)
AU (1) AU2005276355B2 (es)
BR (1) BRPI0513923A (es)
CA (1) CA2574517A1 (es)
CY (1) CY1108878T1 (es)
DE (1) DE602005011818D1 (es)
DK (1) DK1773829T3 (es)
ES (1) ES2319918T3 (es)
FR (1) FR2873693B1 (es)
HR (1) HRP20090160T1 (es)
IL (1) IL180797A (es)
MX (1) MX2007001023A (es)
PE (1) PE20060575A1 (es)
PL (1) PL1773829T3 (es)
PT (1) PT1773829E (es)
RU (1) RU2389727C2 (es)
SI (1) SI1773829T1 (es)
TW (1) TW200617005A (es)
UY (1) UY29040A1 (es)
WO (1) WO2006021657A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2873691B1 (fr) * 2004-07-29 2006-10-06 Sanofi Synthelabo Derives d'amino-piperidine, leur preparation et leur application en therapeutique
FR2873690B1 (fr) * 2004-07-29 2006-10-13 Sanofi Synthelabo Derives d'oxopiperidine, leur preparation et leur application en therapeutique
WO2007028770A1 (en) * 2005-09-05 2007-03-15 Neurosearch A/S Monoamine neurotransmitter re-uptake inhibitors for neuroprotection in patients suffering from an advanced stage of a mental disease
EP2000139A1 (en) * 2007-06-07 2008-12-10 Novartis AG Stabilized amorphous forms of imatinib mesylate
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
PL2074120T3 (pl) * 2007-10-25 2010-08-31 Exelixis Inc Związki tropanu
US8153653B2 (en) * 2010-06-22 2012-04-10 Hoffmann-La Roche Inc. Amido-tropane derivatives
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
EP2683701B1 (de) 2011-03-08 2014-12-24 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120051A1 (de) 2011-03-08 2012-09-13 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2263173T3 (es) * 1996-10-30 2006-12-01 Schering Corporation Derivados piperazino como antagonistas de neurokinina.
US5968929A (en) * 1996-10-30 1999-10-19 Schering Corporation Piperazino derivatives as neurokinin antagonists
CA2432988A1 (en) * 2001-01-23 2002-08-01 Cristina Garcia-Paredes Melanocortin receptor agonists
CA2453609C (en) * 2001-07-18 2010-05-04 Merck & Co., Inc. Bridged piperidine derivatives as melanocortin receptor agonists
DE60308996T2 (de) * 2002-01-23 2007-05-10 Eli Lilly And Co., Indianapolis Melanocortinrezeptoragonisten

Also Published As

Publication number Publication date
AU2005276355B2 (en) 2011-08-25
ATE417846T1 (de) 2009-01-15
AU2005276355A1 (en) 2006-03-02
WO2006021657A1 (fr) 2006-03-02
US7569582B2 (en) 2009-08-04
DE602005011818D1 (de) 2009-01-29
CN101010320A (zh) 2007-08-01
IL180797A0 (en) 2007-06-03
UY29040A1 (es) 2006-02-24
BRPI0513923A (pt) 2008-05-20
US20070191361A1 (en) 2007-08-16
DK1773829T3 (da) 2009-04-20
TW200617005A (en) 2006-06-01
HRP20090160T1 (en) 2009-05-31
PL1773829T3 (pl) 2009-06-30
PT1773829E (pt) 2009-03-26
ES2319918T3 (es) 2009-05-14
MX2007001023A (es) 2007-04-16
IL180797A (en) 2011-02-28
FR2873693A1 (fr) 2006-02-03
CY1108878T1 (el) 2014-07-02
EP1773829A1 (fr) 2007-04-18
CA2574517A1 (fr) 2006-03-02
AR050019A1 (es) 2006-09-20
CN101010320B (zh) 2011-11-16
FR2873693B1 (fr) 2006-09-15
SI1773829T1 (sl) 2009-06-30
RU2007107372A (ru) 2008-09-10
EP1773829B1 (fr) 2008-12-17
RU2389727C2 (ru) 2010-05-20
KR20070047803A (ko) 2007-05-07
JP2008508242A (ja) 2008-03-21

Similar Documents

Publication Publication Date Title
PE20060575A1 (es) Derivados de amino-tropano como agonistas de los receptores de melanocortinas
ECSP055964A (es) Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6
CY1105579T1 (el) Kαρβαμιδο - υποκατεστημενες πυραζολοπυριδινες
MXPA05010189A (es) Analogos de prostaglandina como antagonistas del receptor ep4.
GB0517191D0 (en) Compounds
CY1107956T1 (el) Χρηση υποκατεστημενων 2-αμινοτετραλινιων για την προληπτικη αντιμετωπιση της νοσου του παρκινσον
PE20070519A1 (es) Derivados de fenilmorfolina y feniltiomorfolina como agonistas de adrenoreceptores alfa 2c
PE20081316A1 (es) COMPUESTOS HETEROCICLICOS QUE MODULAN LA ACTIVIDAD DE LA ESTEROIL-CoA-DESATURASA
CR7743A (es) Nuevos compuestos de oxazol y tiazol como inhibidorea del factor de crecimiento transformador (tgf)
PE20060500A1 (es) Derivados de heteroaril sulfamida benzo-fusionada como anticonvulsivantes
NO20033145D0 (no) Purinderivater som purinergiske reseptorantagonister
PE20081409A1 (es) Antagonistas del receptor de progesterona
PE20060590A1 (es) COMPUESTOS ESTEROIDALES 15ß-SUSTITUIDOS CON ACTIVIDAD SELECTIVA DEL RECEPTOR DE ESTROGENOS
PE20080361A1 (es) Compuestos derivados de purina como activadores del receptor de adenosina a2a
PE20061353A1 (es) Compuestos de sulfonamida-tiazolopiridina como activadores de glucocinasa
EA201001595A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
PE20121158A1 (es) Derivados de feniletinilo como moduladores alostericos positivos (map)
CY1108808T1 (el) Ενωσεις μοτιλιδης
PE20050420A1 (es) Fenacilo 2-hidroxi-3-diaminoalcanos
PE20100737A1 (es) Nuevos compuestos
UY29802A1 (es) Análogos de la feniletilamina y su uso en el tratamiento del glaucoma
PE20071251A1 (es) Derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
HUP0301773A2 (hu) Apomorfinszármazékok és alkalmazásaik
MX2009005507A (es) Derivados de espiro-piperidina.
PE20080941A1 (es) Compuestos triciclicos como agonistas del receptor de melatonina

Legal Events

Date Code Title Description
FA Abandonment or withdrawal